Kura Oncology IPO

11/4/2015

IPO

$50,000,000

We currently expect that we will use the net proceeds from this offering as follows: to fund the completion of our Phase 2 clinical trials of tipifarnib in patients who have solid tumors with HRAS mutations and in patients with PTCL; to fund our planned Phase 2 clinical trial of tipifarnib in patients with lower risk MDS; to fund our ongoing ERK inhibitor program; to fund the initiation of our companion diagnostic program to aid in the selection of patients with HRAS mutant tumors and for additional indications; to fund research and preclinical development of our other product candidates; and for general corporate purposes, including general and administrative expenses, capital expenditures, working capital and prosecution and maintenance of our intellectual property.

Publicly-held

Biopharmaceutical

3033 Science Park Rd. 220
San Diego, CA 92121
USA

At Kura Oncology (NASDAQ: KURA), we are committed to realizing the promise of precision medicines for cancer. The genomics revolution is transforming how we treat cancer.